An MBA 699 Module 4 industry and competitor analysis: a five forces table for biologics contract manufacturing, a competitor comparison, a resource test of the company's strengths and the implications for which buyers to approach. Searches like "mba 699 module 4 assignment", "mba699 module 4 industry and competitor analysis" and "mba 699 module 4 example" land here.
The MBA 699 Module 4 example, in full
Where Prairieview Stands: Industry and Competitor Analysis of Biologics Contract Manufacturing
[Student Name]
Southern New Hampshire University
MBA 699: Strategic Opportunity Management
Module Four Assignment
[Instructor Name]
[Date]
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
Where Prairieview Stands: Industry and Competitor Analysis of Biologics Contract Manufacturing
Purpose and Industry Definition
The guiding coalition's next step toward an exit recommendation is to identify buyers, and buyers can only be judged once the company's position in its industry is clear. Prairieview competes in contract development and manufacturing of biologics: producing antibodies and other protein drugs for pharmaceutical and biotechnology clients, along with process development and quality testing. Its two Indianapolis plants run single-use bioreactors of up to 2,000 liters, serving clients from late clinical trials through early commercial supply. This report examines the industry's structure, the competitors Prairieview meets and the resources that set it apart.
Five Competitive Forces
Porter (2008) traced an industry's long-run profitability to five pressures: how fiercely incumbents compete, how easily newcomers can get in, how much bargaining strength customers and suppliers hold, and how readily other products can take the industry's place. Table 1 rates each for Prairieview's segment.
Table 1
Five Forces in Biologics Contract Manufacturing
| Force | Intensity | Evidence | Implication for value |
|---|---|---|---|
| Rivalry | Moderate to high | Large global producers compete for commercial volume; mid-size firms compete on flexibility and speed | Scale alone does not win; specialization and reliability do |
| Threat of new entrants | Low to moderate | New plants take years and large capital; FDA approval of each process is required | Existing approved capacity is scarce and valuable |
| Power of customers | Moderate | Large pharmaceutical clients negotiate hard, but switching a commercial product's manufacturer requires regulatory filings | Long product lifecycles create sticky revenue |
| Power of suppliers | Moderate | Single-use bags, media and resins come from a few specialized suppliers | Supply agreements and inventory practices affect margin |
| Threat of substitutes | Low to moderate | Clients can build in-house capacity; some shift to other drug types | Clients' make-or-buy decisions set demand |
Note. Assessment by the business development team using public industry information and Prairieview's commercial data.
What the Forces Mean
The segment is moderately attractive, and its most valuable feature is the difficulty of switching. Once a client's drug is approved with Prairieview named as manufacturer, moving production elsewhere requires new validation and regulatory submissions that take many months. Every commercial product Prairieview makes is, in effect, a multiyear contract protected by regulation. The main pressures come from large rivals competing for the same commercial programs and from clients deciding whether to build their own plants. The industry has also been consolidating, with operating companies and investors buying manufacturers to secure capacity, as Thermo Fisher Scientific did with Patheon in 2017 and Novo Holdings did with Catalent in 2024. That activity suggests buyer interest in approved capacity is real.
Competitor Comparison
Prairieview meets three kinds of competitors. The global leaders, among them Lonza, Samsung Biologics, WuXi Biologics and Fujifilm Diosynth Biotechnologies, operate very large stainless steel and single-use plants on several continents and win the largest commercial programs. Mid-size U.S. and European contract manufacturers compete with Prairieview for clinical and early commercial work. Clients' own plants are the third competitor, since each program kept in-house is one Prairieview cannot win. Table 2 compares Prairieview with the first two groups on the factors clients weigh most.
Table 2
Prairieview Compared With Competitor Groups
| Factor | Global leaders | Mid-size rivals | Prairieview |
|---|---|---|---|
| Capacity for large commercial volumes | Strong | Limited | Limited |
| Speed from contract to first batch | Moderate | Varies | Strong |
| U.S.-based supply | Partial | Varies | Strong |
| Regulatory inspection record | Generally strong | Varies | Strong: last two FDA inspections without observations |
| Workforce stability | Varies | Varies | Weak: 20% manufacturing attrition |
| Price | Competitive at scale | Competitive | Premium for speed |
Note. Composite assessment. Prairieview's inspection and attrition figures come from internal records.
Resources a Buyer Could Not Easily Copy
Barney (1991) held that a firm keeps an edge only through resources that create value, that few rivals hold, that others cannot readily imitate and that have no ready substitute. Applying that test, three Prairieview resources stand out. Its approved commercial processes, currently seven client products, are valuable and effectively impossible to copy without the clients' cooperation and new regulatory filings. Its inspection record is valuable and hard to imitate quickly, since it reflects years of quality practice. Its experienced process development team, the 240 scientists with low turnover, is rare in the region and would take years to assemble. Other strengths, such as single-use equipment and U.S. location, are valuable but available to any competitor willing to invest.
One weakness undermines the resources. Manufacturing turnover of 20 percent threatens the consistency that the inspection record depends on, and a buyer will see that connection.
Implications for the Buyer Search
The analysis points to buyers who would value approved capacity, speed and regulatory strength, and who cannot easily obtain them elsewhere. Three profiles fit. A large contract manufacturer seeking U.S.-based mid-scale capacity could fold Prairieview into its network and offer its clients a domestic option. A pharmaceutical or biotechnology company with a growing biologics pipeline could secure supply for its own products, although Prairieview's existing clients might object to their manufacturer being owned by a competitor. A private equity investor could buy Prairieview as a platform for further acquisitions of mid-size manufacturers. Haspeslagh and Jemison (1991) emphasized that value in acquisitions is created after the deal through the transfer of capabilities, which means the right buyer is the one whose plan depends on Prairieview's hard-to-copy resources rather than on cutting them. The next milestone will research specific buyers in each group against these criteria.
What to Strengthen Before Buyers Look
The analysis also shows where Prairieview can raise its value before any buyer is approached. The most direct step is reducing manufacturing turnover, since a stable workforce protects the inspection record and the delivery reliability that justify premium pricing. A second step is documenting the switching protection: a clear summary of each commercial product, its remaining patent and contract life and the regulatory steps a client would need to move it would let buyers see the durability of revenue without guessing. A third is securing longer supply agreements for single-use materials, which would reduce a risk buyers will ask about. None of these steps requires new capital on the scale of a plant expansion, and each would appear in due diligence as evidence that management understands where the company's value lies.
Limits of the Analysis
Industry information for this segment comes largely from company announcements and trade sources, which are not always consistent, and competitors' capacity and pricing are partly estimated. Demand for contract manufacturing also depends on clinical trial outcomes and funding for biotechnology companies, both of which can change quickly. The conclusions should be revisited if a major client's product fails in late trials or if funding conditions for biotechnology tighten further.
References
Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of Management, 17(1), 99-120. https://doi.org/10.1177/014920639101700108
Haspeslagh, P. C., & Jemison, D. B. (1991). Managing acquisitions: Creating value through corporate renewal. Free Press.
Porter, M. E. (2008). The five competitive forces that shape strategy. Harvard Business Review, 86(1), 78-93.
How this MBA 699 Module 4 example is structured
The report defines the industry, then applies the five forces in a single table with an implication for each force. A competitor comparison places the company among the types of rivals it meets. The resource analysis asks which strengths a buyer could not easily build or buy elsewhere, and the conclusion translates that into a buyer profile for the next milestone.
Get MBA 699 Module 4 written to your instructions
Send your MBA 699 Module 4 instructions and rubric. An industry and competitor analysis for your scenario comes back within 24 to 48 hours; the first is free. The paper above is an original model document written by our desk, not a submitted student paper and not an official Southern New Hampshire University document.
MBA 699 Module 4 questions, answered
What is MBA 699 Module 4 usually about?
Around this point in the capstone, work typically turns to researching the industry and competitors of the scenario company, so that the later buyer research and acquisition road map rest on an understanding of where the company stands in its market.
What does a contract manufacturer of biologics do?
It produces biologic drugs, such as antibodies and other proteins made in living cells, on behalf of pharmaceutical and biotechnology companies that lack the capacity or prefer not to build their own plants. Many also offer process development, testing and regulatory support.
Why use a resource-based test as well as five forces?
Five forces describe how attractive an industry is overall. A resource-based test asks what makes one company different within it. For a sale, the second question matters most, because buyers pay for what they cannot easily obtain elsewhere.